43
Participants
Start Date
December 18, 2015
Primary Completion Date
February 2, 2021
Study Completion Date
July 13, 2022
Avelumab
Administered by IV once every two weeks in doses of either 5 mg/kg or 10 mg/kg
PF-06463922
Tablets taken orally once every day in doses of either 100mg, 75mg, or 50mg.
Crizotinib
Capsules. Taken orally once or twice every day in doses of either 200mg or 250mg.
Chris O'Brien Lifehouse, Camperdown
Peter MacCallum Cancer Centre, Melbourne
Royal Melbourne Hospital, Parkville
The Prince Charles Hospital, Chermside
National Cancer Center, Goyang-si
Emory University Hospital Midtown, Atlanta
Emory University Hospital, Atlanta
The Emory Clinic, Atlanta
Winship Cancer Institute of Emory University, Atlanta
Tennessee Oncology, PLLC, Nashville
Massachusetts General Hospital, Boston
Ophthalmic Consultants of Boston Inc (OCB), Boston
Aichi cancer center central hospital, Nagoya
National Hospital Organization Kyushu Cancer Center, Fukuoka
The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo
Asan Medical Center, Seoul
Samsung Medical Center, Seoul
Institut Catala d'Oncologia de Badalona, Badalona
Hospital Quiron Barcelona, Barcelona
Hospital Universitari de la Vall d'Hebron, Barcelona
Lead Sponsor
Pfizer
INDUSTRY